LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 143

Search options

  1. Book: Treating autism spectrum disorders

    Posey, David J.

    (Child and adolescent psychiatric clinics of North America ; 17,4)

    2008  

    Author's details guest ed. David J. Posey
    Series title Child and adolescent psychiatric clinics of North America ; 17,4
    Collection
    Language English
    Size XVIII S., S. 713 - 932
    Publisher Saunders
    Publishing place Philadelphia u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT015703236
    ISBN 1-4160-6278-5 ; 978-1-4160-6278-3
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Article ; Online: Corrigendum: Personalized digital intervention for depression based on social rhythm principles adds significantly to outpatient treatment.

    Frank, Ellen / Wallace, Meredith L / Matthews, Mark J / Kendrick, Jeremy / Leach, Jeremy / Moore, Tara / Aranovich, Gabriel / Choudhury, Tanzeem / Shah, Nirav R / Framroze, Zeenia / Posey, Greg / Burgess, Samuel A / Kupfer, David J

    Frontiers in digital health

    2023  Volume 5, Page(s) 1136316

    Abstract: This corrects the article DOI: 10.3389/fdgth.2022.870522.]. ...

    Abstract [This corrects the article DOI: 10.3389/fdgth.2022.870522.].
    Language English
    Publishing date 2023-03-16
    Publishing country Switzerland
    Document type Published Erratum
    ISSN 2673-253X
    ISSN (online) 2673-253X
    DOI 10.3389/fdgth.2023.1136316
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Organizational science and cybersecurity: abundant opportunities for research at the interface.

    Dalal, Reeshad S / Howard, David J / Bennett, Rebecca J / Posey, Clay / Zaccaro, Stephen J / Brummel, Bradley J

    Journal of business and psychology

    2021  Volume 37, Issue 1, Page(s) 1–29

    Abstract: Cybersecurity is an ever-present problem for organizations, but organizational science has barely begun to enter the arena of cybersecurity research. As a result, the "human factor" in cybersecurity research is much less studied than its technological ... ...

    Abstract Cybersecurity is an ever-present problem for organizations, but organizational science has barely begun to enter the arena of cybersecurity research. As a result, the "human factor" in cybersecurity research is much less studied than its technological counterpart. The current manuscript serves as an introduction and invitation to cybersecurity research by organizational scientists. We define cybersecurity, provide definitions of key cybersecurity constructs relevant to employee behavior, illuminate the unique opportunities available to organizational scientists in the cybersecurity arena (e.g., publication venues that reach new audiences, novel sources of external funding), and provide overall conceptual frameworks of the antecedents of employees' cybersecurity behavior. In so doing, we emphasize both end-users of cybersecurity in organizations and employees focused specifically on cybersecurity work. We provide an expansive agenda for future organizational science research on cybersecurity-and we describe the benefits such research can provide not only to cybersecurity but also to basic research in organizational science itself. We end by providing a list of potential objections to the proposed research along with our responses to these objections. It is our hope that the current manuscript will catalyze research at the interface of organizational science and cybersecurity.
    Language English
    Publishing date 2021-02-04
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2016738-6
    ISSN 1573-353X ; 0889-3268
    ISSN (online) 1573-353X
    ISSN 0889-3268
    DOI 10.1007/s10869-021-09732-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Personalized digital intervention for depression based on social rhythm principles adds significantly to outpatient treatment.

    Frank, Ellen / Wallace, Meredith L / Matthews, Mark J / Kendrick, Jeremy / Leach, Jeremy / Moore, Tara / Aranovich, Gabriel / Choudhury, Tanzeem / Shah, Nirav R / Framroze, Zeenia / Posey, Greg / Burgess, Samuel A / Kupfer, David J

    Frontiers in digital health

    2022  Volume 4, Page(s) 870522

    Abstract: We conducted a 16-week randomized controlled trial in psychiatric outpatients with a lifetime diagnosis of a mood and/or anxiety disorder to measure the impact of a first-of-its-kind precision digital intervention software solution based on social rhythm ...

    Abstract We conducted a 16-week randomized controlled trial in psychiatric outpatients with a lifetime diagnosis of a mood and/or anxiety disorder to measure the impact of a first-of-its-kind precision digital intervention software solution based on social rhythm regulation principles. The full intent-to-treat (ITT) sample consisted of 133 individuals, aged 18-65. An exploratory sub-sample of interest was those individuals who presented with moderately severe to severe depression at study entry (baseline PHQ-8 score ≥15;
    Language English
    Publishing date 2022-09-02
    Publishing country Switzerland
    Document type Journal Article
    ISSN 2673-253X
    ISSN (online) 2673-253X
    DOI 10.3389/fdgth.2022.870522
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Two-dimensional heavy fermions in the van der Waals metal CeSiI.

    Posey, Victoria A / Turkel, Simon / Rezaee, Mehdi / Devarakonda, Aravind / Kundu, Asish K / Ong, Chin Shen / Thinel, Morgan / Chica, Daniel G / Vitalone, Rocco A / Jing, Ran / Xu, Suheng / Needell, David R / Meirzadeh, Elena / Feuer, Margalit L / Jindal, Apoorv / Cui, Xiaomeng / Valla, Tonica / Thunström, Patrik / Yilmaz, Turgut /
    Vescovo, Elio / Graf, David / Zhu, Xiaoyang / Scheie, Allen / May, Andrew F / Eriksson, Olle / Basov, D N / Dean, Cory R / Rubio, Angel / Kim, Philip / Ziebel, Michael E / Millis, Andrew J / Pasupathy, Abhay N / Roy, Xavier

    Nature

    2024  Volume 625, Issue 7995, Page(s) 483–488

    Abstract: Heavy-fermion metals are prototype systems for observing emergent quantum phases driven by electronic ... ...

    Abstract Heavy-fermion metals are prototype systems for observing emergent quantum phases driven by electronic interactions
    Language English
    Publishing date 2024-01-17
    Publishing country England
    Document type Journal Article
    ZDB-ID 120714-3
    ISSN 1476-4687 ; 0028-0836
    ISSN (online) 1476-4687
    ISSN 0028-0836
    DOI 10.1038/s41586-023-06868-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Differential ABC transporter expression during hematopoiesis contributes to neutrophil-biased toxicity of Aurora kinase inhibitors.

    Chou, David B / Furlong, Brooke A / Posey, Ryan R / Kyprianou, Christos / O'Sullivan, Lucy R / David, Rhiannon / Randle, Suzanne J / Polanska, Urszula M / Travers, Jon / Urosevic, Jelena / Hutchinson, John N / Che, Jianwei / Howley, Anna M / Hasserjian, Robert P / Prantil-Baun, Rachelle / Ingber, Donald E

    Nature communications

    2022  Volume 13, Issue 1, Page(s) 6021

    Abstract: Drug-induced cytopenias are a prevalent and significant issue that worsens clinical outcomes and hinders the effective treatment of cancer. While reductions in blood cell numbers are classically associated with traditional cytotoxic chemotherapies, they ... ...

    Abstract Drug-induced cytopenias are a prevalent and significant issue that worsens clinical outcomes and hinders the effective treatment of cancer. While reductions in blood cell numbers are classically associated with traditional cytotoxic chemotherapies, they also occur with newer targeted small molecules and the factors that determine the hematotoxicity profiles of oncologic drugs are not fully understood. Here, we explore why some Aurora kinase inhibitors cause preferential neutropenia. By studying drug responses of healthy human hematopoietic cells in vitro and analyzing existing gene expression datasets, we provide evidence that the enhanced vulnerability of neutrophil-lineage cells to Aurora kinase inhibition is caused by early developmental changes in ATP-binding cassette (ABC) transporter expression. These data show that hematopoietic cell-intrinsic expression of ABC transporters may be an important factor that determines how some Aurora kinase inhibitors affect the bone marrow.
    MeSH term(s) ATP Binding Cassette Transporter, Subfamily G, Member 2 ; ATP-Binding Cassette Transporters/genetics ; ATP-Binding Cassette Transporters/metabolism ; Adenosine Triphosphate ; Aurora Kinases/metabolism ; Hematopoiesis/genetics ; Humans ; Neoplasm Proteins/metabolism ; Neutrophils/metabolism ; Protein Kinase Inhibitors/pharmacology
    Chemical Substances ATP Binding Cassette Transporter, Subfamily G, Member 2 ; ATP-Binding Cassette Transporters ; Neoplasm Proteins ; Protein Kinase Inhibitors ; Adenosine Triphosphate (8L70Q75FXE) ; Aurora Kinases (EC 2.7.11.1)
    Language English
    Publishing date 2022-10-12
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S. ; Research Support, N.I.H., Extramural
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-022-33672-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder.

    McDougle, Christopher J / Thom, Robyn P / Ravichandran, Caitlin T / Palumbo, Michelle L / Politte, Laura C / Mullett, Jennifer E / Keary, Christopher J / Erickson, Craig A / Stigler, Kimberly A / Mathieu-Frasier, Lauren / Posey, David J

    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

    2022  Volume 47, Issue 6, Page(s) 1263–1270

    Abstract: This study was a 10-week double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in youth with autism spectrum disorder (ASD). Participants were ages 5 to 17 years with ASD and clinically significant anxiety (Pediatric Anxiety Rating ... ...

    Abstract This study was a 10-week double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in youth with autism spectrum disorder (ASD). Participants were ages 5 to 17 years with ASD and clinically significant anxiety (Pediatric Anxiety Rating Scale [PARS] score ≥10). Thirty participants were randomized to mirtazapine (7.5-45 mg/day) or placebo in a 2:1 ratio. The co-primary outcome measures were the PARS and the Clinical Global Impressions-Improvement subscale (CGI-I). Mirtazapine resulted in a statistically significant within group decrease in anxiety on the PARS (ES 1.76, p < 0.001). The improvement in PARS score for mirtazapine versus placebo was clinically meaningful but not statistically significant (ES = 0.63, p = 0.64). Forty-seven percent of participants assigned to mirtazapine (95% CI 22%: 74%) and 20% assigned to placebo (95% CI 2%: 60%) were rated "much improved" (CGI-I = 2) or "very much improved" (CGI-I = 1) for anxiety, p = 0.46. No statistically significant differences in mean 10-week changes between mirtazapine and placebo occurred on any outcome measure. There were no statistically significant differences in adverse effect frequency between mirtazapine and placebo. The results are consistent with mirtazapine's safety and tolerability and meet three of four pre-specified indicators of efficacy (statistically significant change in total PARS score for mirtazapine, numerically greater reduction in total PARS score for mirtazapine than placebo, numerically higher number of responders to mirtazapine than placebo, but not greater than 50% of participants receiving mirtazapine rated as responders). Implementation of a larger randomized controlled trial of mirtazapine for the treatment of anxiety in this population is supported.Clinical trial registration information: Mirtazapine Treatment of Anxiety in Children and Adolescents with Pervasive Developmental Disorders; https://clinicaltrials.gov

    NCT01302964.
    MeSH term(s) Adolescent ; Anxiety/drug therapy ; Anxiety Disorders/drug therapy ; Autism Spectrum Disorder/complications ; Autism Spectrum Disorder/drug therapy ; Child ; Child, Preschool ; Double-Blind Method ; Humans ; Mirtazapine/therapeutic use ; Pilot Projects ; Treatment Outcome
    Chemical Substances Mirtazapine (A051Q2099Q)
    Language English
    Publishing date 2022-03-03
    Publishing country England
    Document type Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 639471-1
    ISSN 1740-634X ; 0893-133X
    ISSN (online) 1740-634X
    ISSN 0893-133X
    DOI 10.1038/s41386-022-01295-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Molecular Evaluation of Fluoroquinolone Resistance in Serial Mycobacterium tuberculosis Isolates from Individuals Diagnosed with Multidrug-Resistant Tuberculosis.

    Willby, Melisa / Chopra, Paige / Lemmer, Darrin / Klein, Katherine / Dalton, Tracy L / Engelthaler, David M / Cegielski, J Peter / Posey, James E

    Antimicrobial agents and chemotherapy

    2020  Volume 65, Issue 1

    Abstract: Fluoroquinolones (FQ) are crucial components of multidrug-resistant tuberculosis (MDR TB) treatment. Differing levels of resistance are associated with specific mutations within ... ...

    Abstract Fluoroquinolones (FQ) are crucial components of multidrug-resistant tuberculosis (MDR TB) treatment. Differing levels of resistance are associated with specific mutations within the
    MeSH term(s) Antitubercular Agents/pharmacology ; DNA Gyrase/genetics ; Drug Resistance, Multiple, Bacterial/genetics ; Fluoroquinolones/pharmacology ; Humans ; Microbial Sensitivity Tests ; Mycobacterium tuberculosis/genetics ; Tuberculosis, Multidrug-Resistant/drug therapy
    Chemical Substances Antitubercular Agents ; Fluoroquinolones ; DNA Gyrase (EC 5.99.1.3)
    Language English
    Publishing date 2020-12-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 217602-6
    ISSN 1098-6596 ; 0066-4804
    ISSN (online) 1098-6596
    ISSN 0066-4804
    DOI 10.1128/AAC.01663-20
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Variant-level matching for diagnosis and discovery: Challenges and opportunities.

    Rodrigues, Eliete da S / Griffith, Sean / Martin, Renan / Antonescu, Corina / Posey, Jennifer E / Coban-Akdemir, Zeynep / Jhangiani, Shalini N / Doheny, Kimberly F / Lupski, James R / Valle, David / Bamshad, Michael J / Hamosh, Ada / Sheffer, Assaf / Chong, Jessica X / Einhorn, Yaron / Cupak, Miro / Sobreira, Nara

    Human mutation

    2022  Volume 43, Issue 6, Page(s) 782–790

    Abstract: Here we describe MyGene2, Geno2MP, VariantMatcher, and Franklin; databases that provide variant-level information and phenotypic features to researchers, clinicians, healthcare providers and patients. Following the footsteps of the Matchmaker Exchange ... ...

    Abstract Here we describe MyGene2, Geno2MP, VariantMatcher, and Franklin; databases that provide variant-level information and phenotypic features to researchers, clinicians, healthcare providers and patients. Following the footsteps of the Matchmaker Exchange project that connects exome, genome, and phenotype databases at the gene level, these databases have as one goal to facilitate connection to one another using Data Connect, a standard for discovery and search of biomedical data from the Global Alliance for Genomics and Health (GA4GH).
    MeSH term(s) Databases, Genetic ; Exome/genetics ; Genomics ; Humans ; Information Dissemination ; Phenotype
    Language English
    Publishing date 2022-03-21
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 1126646-6
    ISSN 1098-1004 ; 1059-7794
    ISSN (online) 1098-1004
    ISSN 1059-7794
    DOI 10.1002/humu.24359
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Personalized digital intervention for depression based on social rhythm principles adds significantly to outpatient treatment

    Ellen Frank / Meredith L. Wallace / Mark J. Matthews / Jeremy Kendrick / Jeremy Leach / Tara Moore / Gabriel Aranovich / Tanzeem Choudhury / Nirav R. Shah / Zeenia Framroze / Greg Posey / Samuel A. Burgess / David J. Kupfer

    Frontiers in Digital Health, Vol

    2022  Volume 4

    Abstract: We conducted a 16-week randomized controlled trial in psychiatric outpatients with a lifetime diagnosis of a mood and/or anxiety disorder to measure the impact of a first-of-its-kind precision digital intervention software solution based on social rhythm ...

    Abstract We conducted a 16-week randomized controlled trial in psychiatric outpatients with a lifetime diagnosis of a mood and/or anxiety disorder to measure the impact of a first-of-its-kind precision digital intervention software solution based on social rhythm regulation principles. The full intent-to-treat (ITT) sample consisted of 133 individuals, aged 18–65. An exploratory sub-sample of interest was those individuals who presented with moderately severe to severe depression at study entry (baseline PHQ-8 score ≥15; N = 28). Cue is a novel digital intervention platform that capitalizes on the smartphone's ability to continuously monitor depression-relevant behavior patterns and use each patient's behavioral data to provide timely, personalized “micro-interventions,” making this the first example of a precision digital intervention of which we are aware. Participants were randomly allocated to receive Cue plus care-as-usual or digital monitoring only plus care as usual. Within the full study and depressed-at-entry samples, we fit a mixed effects model to test for group differences in the slope of depressive symptoms over 16 weeks. To account for the non-linear trajectory with more flexibility, we also fit a mixed effects model considering week as a categorical variable and used the resulting estimates to test the group difference in PHQ change from baseline to 16 weeks. In the full sample, the group difference in the slope of PHQ-8 was negligible (Cohen's d = −0.10); however, the Cue group demonstrated significantly greater improvement from baseline to 16 weeks (p = 0.040). In the depressed-at-entry sample, we found evidence for benefit of Cue. The group difference in the slope of PHQ-8 (Cohen's d = −0.72) indicated a meaningfully more rapid rate of improvement in the intervention group than in the control group. The Cue group also demonstrated significantly greater improvement in PHQ-8 from baseline to 16 weeks (p = 0.009). We are encouraged by the size of the intervention effect in those who were acutely ill at ...
    Keywords depression ; treatment ; digital intervention platform ; passive monitoring ; depressive symptoms ; social rhythm disruption ; Medicine ; R ; Public aspects of medicine ; RA1-1270 ; Electronic computers. Computer science ; QA75.5-76.95
    Subject code 796
    Language English
    Publishing date 2022-09-01T00:00:00Z
    Publisher Frontiers Media S.A.
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top